Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer

A recent phase 1 trial showed that treatment with nivolumab before surgery (neoadjuvant treatment) was tolerable in patients with high-risk clear cell renal cell carcinoma (RCC) that had not spread. These results were presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO). The study was a phase 1 trial that looked […]

read more

Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more

Long term follow-up of immune-related adverse events in cancer survivors

In this study carried out at a single hospital 217 cancer patients, who had at least 2 years follow-up data after treatment with immune checkpoint inhibitors (PD-1 or PD-L1), were followed-up long term for adverse events and health-related quality of life (HRQoL). There were 44 patients with renal cell carcinoma (RCC) in the study. Other […]

read more

ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma

In a study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, the tyrosine kinase inhibitor (TKI) savolitinib was shown to be more effective and safer than sunitinib as a treatment for people with papillary renal cell carcinoma (RCC). Papillary renal cell carcinoma accounts for approximately 15% of all RCC, making […]

read more

Targeted therapy dose reduction resulted in better clinical outcomes

A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020. During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the […]

read more

Safety and efficacy of restarting immune checkpoint inhibitors after immune-related adverse events

Immune checkpoint inhibitors can cause a number of immune-related adverse events (irAEs) of various degrees of severity, such as colitis, pneumonitis, hypothyroidism, liver problems and skin rashes. A recent multi-centre, retrospective study published in Journal for Immunotherapy of Cancer investigated the safety and efficacy of re-treatment with immune checkpoint inhibitors, such as nivolumab and ipilimumab […]

read more

Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]

read more

IKCS 2019: Immune related adverse events

Dr Mehmet Asim Bilen of Emory University School of Medicine in Atlanta, USA led a session at the International Kidney Cancer Symposium (IKCS) last month on the diagnosis and management of immune-related toxicity. Immune-related adverse events occur in some patients who are taking immune checkpoint inhibitors for the treatment of advanced renal cell carcinoma (RCC). […]

read more

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was […]

read more

Savolitinib shows promise in first-in-human phase 1 study in solid tumours

Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]

read more
Showing 1 to 10 of 12 results
  TOP